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Resumen– Actualmente, el síndrome de Down es la enfermedad genética más común en Panamá, y las estadísticas más recientes 
indican que en 2010, 474 niños recibieron tratamientos con síndrome de Down en nuestro país. La detección temprana de los 
pacientes con síndrome de Down es extremadamente importante porque permite aplicar tratamientos clínicos apropiados que 
reduzcan las complicaciones que tanto la madre como el bebé tienen durante el embarazo[1]. Sin embargo, no hay biomarcadores 
adaptados a la región, por lo tanto, existen falsos positivos o falsos negativos durante el resultado. Establecer la exactitud de los 
biomarcadores actuales sería una contribución para determinar que podemos mejorar los métodos de cribado actuales. Este artículo 
utiliza datos recientes de cien muestras de biomarcadores y la precisión de sus resultados para sacar conclusiones sobre su uso en 
mujeres panameñas. 
Palabras claves– Ingeniería de Software, Salud Electrónica , Síndrome de Down.  
 
Abstract– Currently, the Down syndrome is the most common genetic condition in Panama, and the most recent statistics indicate 
that in 2010 , 474 children received treatments with Down syndrome in our country. Early detection of Down syndrome patients is 
extremely important because it allows to apply appropriate clinical treatments that reduce complications which both the mother and 
the baby occur during pregnancy [1]. Nevertheless, there is no biomarkers adapted to the region, hence exists false positives or false 
negatives during result. Establish the accuracy of current biomarkers would be a contribution to determine that we can improve on 
current screening methods. This paper uses recent data from one hundred samples of biomarkers and the accuracy of their results 
to draw conclusions about its uses in Panamanian women. 
Keywords– Software Engineering, eHealth, Down’s Syndrome. 
 
1. Introduction 
The Down syndrome [2] was first described in 1866 by 
John Langdon Down in the United Kingdom and his 
cause was discovered in 1959 due to chromosomal 
abnormality known as trisomy 21 however we do not yet 
know why it happens. Down syndrome is a variable 
combination of congenital malformations caused by 
trisomy 21.  It is the most commonly recognized genetic 
cause of mental retardation. Down syndrome occurs at 
conception, across all ethnic and social groups and to 
parents of all ages, but the age factor increases the risk 
more after the mother is 35 years old. 
There are three methods currently used to determine the 
risk of having Downs syndrome being them the 
demographic, using ultrasound and the biochemical 
method. In this work, we intent to improve the result 
obtained in the biochemical methods. 
 
2. Methods for prediction of trisomy 21 
There are  many factors that increase the risk of having 
Down's syndrome [3] [4], [5], for example, the age of the 
mother, if the mother has diabetes or if she smokes, if she 
has had a previous case of syndrome and her ethnic. 
There are a variety of non-invasive and invasive 
techniques available for prenatal diagnosis of trisomy 21. 
The methods for estimate of the risk of the existence of 
trisomy 21 can be divided into invasive and non-invasive 
test. Invasive diagnosis of trisomy 21 requires sampling 
of fetal genetic material through amniocentesis or 
chorionic villus sampling. However, these tests carry a 
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risk of miscarriage and they are therefore reserved for 
pregnancies considered to be at high risk of fetal trisomy 
21. A Non-invasive prenatal test of trisomy 21 is 
researched by using ultrasound to measure the amount of 
fluid at the back of a baby's neck and determines if a 
baby's nasal bone is present. Babies with chromosomal 
disorders may accumulate more fluid at the back of their 
neck during the first trimester. 
Another non-invasive prenatal test of trisomy 21 are 
using fetal specific hormones and proteins biomarkers 
present in the blood of all pregnant women.  This method 
uses, to calculate the risk, a statistical procedure known 
as likelihood  [6] and it uses a lower and upper limits to 
determine if the results of the biomarkers are inside or 
outside of the normal rank. Sometimes the biomarkers 
results are inside the rank of normal classification but too 
close to the limits. In these cases, the system shows a 
negative test but the patients present the illness.  
In medical testing, and generally in binary classification, 
a false positive is an error in data reporting in which a test 
result improperly indicates presence of a condition, such 
as a disease (the result is positive), when in reality it is 
not, while a false negative is an error in which a test result 
improperly indicates no presence of a condition (the 
result is negative), when in reality it is present. 
 
2.1 Biochemical Method 
Prenatal screening for trisomy21 based on the analysis of 
biochemical markers in maternal serum has become an 
established part of obstetric practice in many countries. 
The screening or screening is a probabilistic technique is 
applied to a specific population to determine the risk or 
probability that the object under study suffer from a 
particular disease. The same is done by setting specific 
markers and benchmarks to compare the results against 
the average of the values of the population. When the 
values of the MOM for its acronym in English Multiple 
of Median varies relative to the standard, the result is 
considered positive as presented in figure 1. 
 
2.2 Demographic Method 
The calculation of risk is based on the method of 
calculating risk Likelihood [7] published by Palomaki 
and Haddow combining the a priori risk for maternal age 
obtained from the meta-analysis of Cuckle HS, Wald NJ 
and Thompson, with the likelihood ratio. 
 
 
Figure 1. Model. 
 
2.3  Ultrasound Method 
By this method , as presented in the presence or absence 
of the nasal bone is determined and the measurements 
obtained in the ultrasound vs standard measures 
pertaining to the week of gestation compared established  
[8], [9]. If the measurements are outside the average 
range, it stipulates that there is a risk of trisomy 21.  The 
increased thickness of the nuchal translucency, when the 
measurement exceeds the thickness of 3mm, is 
associated with an increased risk of abnormalities 
chromosomal which in our case is associated with 
trisomy 21. 
 
3. Accuracy and precision of bio-markers 
Biological markers “biomarkers” have been defined by 
Hulka and colleagues [10] as “cellular, biochemical or 
molecular alterations that are measurable in biological 
media such as human tissues, cells, or fluids”. However, 
it is known that no measure is perfect and all 
measurements have some error associated with them. 
It should verify the validity and determine "the sensitivity 
of that marker" and "predictive power" to check what 
number of false positives or false negatives can result in 
a clinical diagnosis.  
Accuracy is how close a measurement comes to the truth, 
represented as a bullseye above.  Accuracy is determined 
by how close a measurement comes to an existing value 
that has been measured by many, many scientists. 
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Precision is how close a measurement comes to another 
measurement.  Precision is determined by a statistical 
method called a standard deviation. 
 
 
Figure 2. Explanation of Accuracy and Precision. 
 
This classic diagram in figure 2 illustrates the possible 
combinations of accuracy and precision.  The precision 
measurements both exhibit tight grouping near some 
portion of the dartboard.  The accurate measurements are 
near the center. To determine if a value is accurate 
compare it to the accepted value.  As these values can be 
anything a concept called percent error has been 
developed.   
Find the difference (subtract) between the accepted value 
and the experimental value, then divide by the accepted 
value as show equation 1. 
 
 100*/)exp(error acceptederimentalaccepted -=
 
(1) 
 
To determine if a value is precise find the average of your 
data, then subtract each measurement from it as show 
equation 2.  This provides a table of deviations. 
 
 )(deviation actualaverage -=  (2) 
 
Standard deviation is how much, on average, each 
measurement differs from each other, formalized as 
standard deviation = (deviations for all measurements 
added together) / number of measurements. A high 
standard deviation indicates low precision and a low 
standard deviation indicates high precision. Then average 
the deviations will give you a value called uncertainty, a 
positive or negative value that says how precise the 
measurement is. 
Uncertainty analysis aims to make a technical 
contribution to decision-making through the 
quantification of uncertainties in the relevant variables, 
alike sensitivity analysis. Throughout the following 
sections deviation values and uncertainty of the data used 
is calculated. 
 
3.1. Biochemical markers 
A Biochemical marker is any measurable biological 
chemical parameter, which allows to know, for example, 
the state of a disease or drug response. 
Many proteins in the maternal circulation have been 
found during the time of pregnancy [11].  Many of these 
are made or modified by the placenta.  Differences in 
levels of some of the proteins have been observed in 
patients carrying a fetus with Down syndrome and 
certain other chromosome abnormalities. 
The discovery of these slight differences in protein levels 
has been largely based on observation- we really don't 
know why they work in most cases.  Nevertheless, we 
can take advantage of these differences in screening 
protocols.  These are referred to as biochemical markers.  
Certain patterns of biochemical markers have been 
associated with fetal Down syndrome as well as other 
conditions. 
It is important to know that these proteins change during 
pregnancy, so interpretation requires a knowledge of the 
gestational age.  Also, the effectiveness of these proteins 
varies with gestational ages.  For example, differences in 
protein levels may be observed during the second 
trimester but not the first, while other proteins show 
differences during the first trimester but not the second. 
 
3.2. Range of the biochemical markers 
As mentioned in [12] the current screening methods 
utilize an upper and lower limit to group a healthy 
population. The chemical markers results are compared 
with these limits. Based on this comparison, if two of this 
group of conditions is presented, the algorithm will throw 
a positive case. Let say in the test, the AFP has a MoM 
of 0.48 (Lower than 0.5) and the HCG has a MoM is 2.62 
(Greater than 2.5) the algorithm will mark the test as 
positive with Down’s syndrome [13]. If the values of the 
MoMs are inside the range, the test diagnostic will be 
negative.  The condition’s value for each marker are 
presented in the table 1. 
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Table 1. Ranges and Meanings of Biomarkers. 
 
Marker Conditions Value 
AFP MoM Bad if less than 0.5 to 2.5 
UE3 MoM Bad if less than  0.5 to 2.5 
HCG-T Bad if greater than 2.5 
INH-A Bad if greater than 2.5 
 
3.3. Link accuracy probability 
The proposed method is based in the study of the bad 
ranges in the chemical markers with the aim to use the 
obtained values of the three markers which gives us more 
reliability in the decision toked. 
As mentioned above the algorithm makes a comparison 
of the markers, if two markers of the three give us 
acceptable values, then the result will be negative. Also, 
if two markers give us abnormal values, then the test is 
marked as positive with high risk. The omission of one 
marker could lead us to those states which have values 
with false positives or false negatives so we need at least 
three of them.  
The difference in the number of markers used influences 
the result obtained in the calculation of the standard 
deviation and therefore in the precision due to the error 
contained. For example, with the values Unconjugates 
Estriol UE3 = 0.49, Alpha Fetoprotein AFP = 0.52, and 
Human Chorionic Gonadotropin HCG = 2.50, we can 
obtain different results depending of the markers used.  
Table 2 contains the results in the standard deviation and 
the error when using two or three markers. 
  
Table 2. Markers, Standard Deviation and Errors. 
 
Markers  Standard 
Deviation 
Error 
UE3, AFP 0.505 56.8376068 
UE3, HCG 1.495 -27.7777778 
AFP, HCG 1.51 -29.0598291 
UE3, AFP, HCG 1.17 0 
 
Figure 3 and 4 shows the corresponding graphs to the 
values obtained in the table 2. 
 
These values were calculated using a sample of the 
chemical markers of one hundred patients with difference 
age and ethnic. 
 
 
Figure 3. Standard Deviation Calculation Graph when 
using two or three markers.  
 
 
 
Figure 4. Error calculation when using two or three 
markers. 
 
The proposed method integrates the three markers with 
the aim to obtain more precision in the result due that 
sometimes the used method presents a gap when the 
values are too close to the limits. For example, if we take 
the same patient having a MoM of AFP of 0.51 and HCG 
2.49, values that are inside the healthy range, the 
algorithm will throw a negative Downs syndrome test.  
However, both markers are very close of the limits so in 
these cases, it is most likely that the patient present a 
Down’s syndrome condition.To work with these three 
markers is necessary to focus in the proximity of the 
value that each marker presents to the limits for to 
compute the result. That is important because when more 
near is the value of the marker to its limits increase the 
probability that the patient has Down Syndrome. An 
example of this case is shown in figure 5: 
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Figure 5. Example of a positive false. 
 
With this value, the test indicates that the patient does not 
has Down Syndrome but its markers are too close to the 
limits which state that the possibility to suffer it is high. 
The decision is taken based on the result of the MoM’s 
value of the three markers. That’s means that each one 
has influence on a third part of the global result. This 
condition leads us to assign equal percent to each one of 
the markers. The percent is calculated for both, the Lower 
Limit and Upper Limit markers, taking in consideration 
the way in which the percent increase for each type of 
chemical marker, until achieving the 100 percent as 
shown in the figure 7. We could not apply the same 
calculation condition for the lower and upper limit 
because the actual rank is not from 0 to 2.5. The current 
rank starts from 0.5 to 2.5 so the formula changes. 
 
Figure 6. Risk increment direction for LL biomarkers. 
 
 
 
Figure 7. Risk increment direction for UL biomarkers. 
 
Each marker has a limit value given for the range of a 
healthy population we use this range for to compute the 
new values for each marker. The next equations compute 
the rate of confidence for each marker according to the 
limit value. That is, markers whose limits value are below 
0.5 denominate as Lower Limits Rate of Confidence (LL) 
are compute by equation 3 and the marker whose MoMs 
limits is upper than 2.5 denominate as Upper Limits Rate 
of Confidence (UL) is compute by equation 4. 
 
 ÷
ø
ö
ç
è
æ
=
elimit valuLower 
0.3333*Value MoM'sMarker -1
LL  (3) 
 
 ÷
ø
ö
ç
è
æ
=
1- elimit valuUpper 
UL
0.3333*1)- Value MoM's(Marker  (4) 
 
Applying the result obtained of the previous equations 
we can compute one result of the three markers 
denominate Test Rate of Confidence (TRC). Equation 5 
compute this final result. 
 
 å += LLULTCR  (5) 
 
To compute the Test Rate of Confidence (TRC) with the 
above equations the following test shown in table 3 was 
selected from our sample data. 
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Table 3. Sample data to compute the test rate of 
confidence TCR. 
 
AFP UE3 HCG 
0.57438 0.66835 2.39302 
 
Applying the equation 3 and 4 for the results of the 
patient presented in the table 3, the percentage of 
confidence for each marker is calculated in the equation 
6, 7 and 8.  
 %37.28
1- 0.5
AFP
0.3333*0.57438)- (1
== ÷
ø
ö
ç
è
æ  (6) 
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0.5
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 %95.30
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0.3333*1)- (2.39302
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After, the confidence rate of the equation 5 is calculated 
as shown in equation 9: 
 
%49.81
%95.30%11.22%37.28
TCR
=
++=
+= å
TCR
TCR
LLUL
 (9) 
 
 
 
Figure 8. Acceptance rate obtained for each marker. 
 
4. Results 
The sum of the value of the confidence rate for all the 
markers is 81.43%. Even though the normal test will 
throw a negative Downs syndrome result because the 
MoMs are inside the healthy range, based on this method, 
we could argue that the mother present a high risk of 
having a baby with this aneuploidy. Figure 8 shown 
graphically the high risk of this values. 
 
5. Conclusion 
This work presents a mathematical model to calculate a 
percentage rate of confidence of the current static method 
applied to calculate the risk of having Down’s syndrome 
or not. This percentage rate of confidence will provide to 
the specialist a clue of how accurate the test is, even 
though it throws a correct output or a false positive or 
false negative case.  
The intention of this work is to provide a second layer of 
estimation to improve the risk estimation and facilitate 
the work of the gynecologist and fetal screening health 
specialist. 
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